[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Nguyen et al., 2015 - Google Patents

Rationally designed small molecules that target both the DNA and RNA causing myotonic dystrophy type 1

Nguyen et al., 2015

Document ID
1902671346829156028
Author
Nguyen L
Luu L
Peng S
Serrano J
Chan H
Zimmerman S
Publication year
Publication venue
Journal of the American Chemical Society

External Links

Snippet

Single-agent, single-target therapeutic approaches are often limited by a complex disease pathobiology. We report rationally designed, multi-target agents for myotonic dystrophy type 1 (DM1). DM1 originates in an abnormal expansion of CTG repeats (CTGexp) in the DMPK …
Continue reading at pubs.acs.org (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

Similar Documents

Publication Publication Date Title
Nguyen et al. Rationally designed small molecules that target both the DNA and RNA causing myotonic dystrophy type 1
Wong et al. Targeting toxic RNAs that cause myotonic dystrophy type 1 (DM1) with a bisamidinium inhibitor
Meyer et al. Small molecule recognition of disease-relevant RNA structures
Bennett et al. Antisense drugs make sense for neurological diseases
Jahromi et al. A novel CUGexp· MBNL1 inhibitor with therapeutic potential for myotonic dystrophy type 1
Gareiss et al. Dynamic combinatorial selection of molecules capable of inhibiting the (CUG) repeat RNA− MBNL1 interaction in vitro: discovery of lead compounds targeting myotonic dystrophy (DM1)
Assimon et al. CB-6644 is a selective inhibitor of the RUVBL1/2 complex with anticancer activity
Haga et al. Small molecule inhibition of miR-544 biogenesis disrupts adaptive responses to hypoxia by modulating ATM-mTOR signaling
Chen et al. Monitoring and modulating mtDNA G-quadruplex dynamics reveal its close relationship to cell glycolysis
Ren et al. Sequence and structural selectivity of nucleic acid binding ligands
Childs-Disney et al. Rational design of bioactive, modularly assembled aminoglycosides targeting the RNA that causes myotonic dystrophy type 1
Lee et al. Controlling the specificity of modularly assembled small molecules for RNA via ligand module spacing: targeting the RNAs that cause myotonic muscular dystrophy
Fornander et al. Minor-groove binding drugs: where is the second Hoechst 33258 molecule?
Yang et al. Animal toxicity of hairpin pyrrole-imidazole polyamides varies with the turn unit
Angelbello et al. A small molecule that binds an RNA repeat expansion stimulates its decay via the exosome complex
Jenquin et al. Furamidine rescues myotonic dystrophy type I associated mis-splicing through multiple mechanisms
Siboni et al. Biological efficacy and toxicity of diamidines in myotonic dystrophy type 1 models
Angelbello et al. Precise targeted cleavage of ar (CUG) repeat expansion in cells by using a small-molecule–deglycobleomycin conjugate
Meyer et al. Oligonucleotide sequential bis-conjugation via click− oxime and click− Huisgen procedures
Morihiro et al. Floxuridine oligomers activated under hypoxic environment
Benhamou et al. Structure-specific cleavage of an RNA repeat expansion with a dimeric small molecule is advantageous over sequence-specific recognition by an oligonucleotide
Makowski et al. Sudemycin K: a synthetic antitumor splicing inhibitor variant with improved activity and versatile chemistry
Pendergraff et al. Locked nucleic acid gapmers and conjugates potently silence ADAM33, an asthma-associated metalloprotease with nuclear-localized mRNA
Taatjes et al. Nuclear targeting and nuclear retention of anthracycline− formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines
Angelbello et al. A toxic RNA templates the synthesis of its own fluorogenic inhibitor by using a bio-orthogonal tetrazine ligation in cells and tissues